Summary
Cellectis SA (Cellectis) is a biopharmaceutical company that offers therapeutic treatment. The company develops treatment based on allogeneic T-cell for the treatment of cancer. Its therapeutic pipeline products include products for hematopoietic tumors such as UCART19, UCART123, UCART33, UCART-BCMA and UCART38; and products for solid tumors include UCART5T4, UCART-EgfrVIII, s-3, s-4, s-5,s-6, and s-7. Cellectis conducts research and development in the field of oncology and gene editing. The company’s engineered T cell can convert a process to a T cell product, resist standard of care and overcome checkpoint inhibitions. Cellectis is headquartered in Paris, France.
Cellectis SA (ALCLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cellectis SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cellectis SA, Medical Devices Deals, 2011 to YTD 2017 10
Cellectis SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cellectis SA, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Cellectis and MabQuest Enter into Research Agreement 13
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 13
Weill Cornell Medical Enters into Research Agreement with Cellectis 14
ModiQuest Research Enters into Co-Development Agreement with Cellectis Bioresearch 15
Pfizer Enters into Development Agreement with Cellectis 16
Cellectis Enters Into Co-Development Agreement With Servier 17
Cellectis Enters Into Co-Development Agreement With University College London 18
Medicago Enters Into Co-Development Agreement With Cellectis 19
Cellectis bioresearch Enters Into Co-Development Agreement With Syngene International 19
CYTOO, Cellectis Bioresearch Enter Into Co-Development Agreement With CEA 20
Cellectis Enters Into Co-Development Agreement With Precision Genome Engineering 21
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 21
Cellectis Enters Into Co-Development Agreement With Etablissement Francais 22
Licensing Agreements 23
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 23
Servier Exercises Option for Licensing Agreement with Cellectis 24
Cellectis Enters into Licensing Agreement with Ohio State Innovation Foundation 25
Cellectis Enters into Licensing Agreement with Thermo Fisher Scientific for Gene Editing Technology 25
Cellectis Enters into Licensing Agreement with genOway 26
Cellectis Enters Into Licensing Agreement With Iowa State University For TAL Technology 27
Cellectis Enters Into Licensing Agreement With Novartis 28
Cellectis Enters Into Research and Licensing Agreement With VitamFero 28
Cellectis Enters Into Licensing Agreement With University Of Minnesota 29
Equity Offering 30
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 30
Cellectis Raises USD16.5 Million upon Exercise of Warrants 32
Cellectis Completes Private Placement Of Shares For US$28.3 Million 33
Debt Offering 34
Cellectis Completes Private Placement Of Convertible Bonds For US$68.8 Million 34
Acquisition 35
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 35
Takara Bio Acquires Cellectis, Biotech Company 35
Cellectis Completes Acquisition Of Cellartis For US$38.2 Million 37
Caisse des Depots To Invest US$8.5 Million In Ectycell 39
Cellectis SA - Key Competitors 40
Key Employees 41
Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Tables
Cellectis SA, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cellectis SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cellectis SA, Deals By Therapy Area, 2011 to YTD 2017 9
Cellectis SA, Medical Devices Deals, 2011 to YTD 2017 10
Cellectis SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cellectis and MabQuest Enter into Research Agreement 13
Cellectis Enters into R&D Agreement with The University of Texas MD Anderson Cancer Center 13
Weill Cornell Medical Enters into Research Agreement with Cellectis 14
ModiQuest Research Enters into Co-Development Agreement with Cellectis Bioresearch 15
Pfizer Enters into Development Agreement with Cellectis 16
Cellectis Enters Into Co-Development Agreement With Servier 17
Cellectis Enters Into Co-Development Agreement With University College London 18
Medicago Enters Into Co-Development Agreement With Cellectis 19
Cellectis bioresearch Enters Into Co-Development Agreement With Syngene International 19
CYTOO, Cellectis Bioresearch Enter Into Co-Development Agreement With CEA 20
Cellectis Enters Into Co-Development Agreement With Precision Genome Engineering 21
Cellectis Bioresearch Enters Into Distribution Agreement With Wako Pure Chemical 21
Cellectis Enters Into Co-Development Agreement With Etablissement Francais 22
Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 23
Servier Exercises Option for Licensing Agreement with Cellectis 24
Cellectis Enters into Licensing Agreement with Ohio State Innovation Foundation 25
Cellectis Enters into Licensing Agreement with Thermo Fisher Scientific for Gene Editing Technology 25
Cellectis Enters into Licensing Agreement with genOway 26
Cellectis Enters Into Licensing Agreement With Iowa State University For TAL Technology 27
Cellectis Enters Into Licensing Agreement With Novartis 28
Cellectis Enters Into Research and Licensing Agreement With VitamFero 28
Cellectis Enters Into Licensing Agreement With University Of Minnesota 29
Cellectis Prices Public Offering of American Depositary Shares for USD228.25 Million 30
Cellectis Raises USD16.5 Million upon Exercise of Warrants 32
Cellectis Completes Private Placement Of Shares For US$28.3 Million 33
Cellectis Completes Private Placement Of Convertible Bonds For US$68.8 Million 34
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 35
Takara Bio Acquires Cellectis, Biotech Company 35
Cellectis Completes Acquisition Of Cellartis For US$38.2 Million 37
Caisse des Depots To Invest US$8.5 Million In Ectycell 39
Cellectis SA, Key Competitors 40
Cellectis SA, Key Employees 41
Cellectis SA, Subsidiaries 42
List of Figures
Cellectis SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cellectis SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cellectis SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cellectis SA, Medical Devices Deals, 2011 to YTD 2017 10
